Skip to main content
Institute of Dentistry - Barts and The London

Professor Farida Fortune, CBE, BDS, MBBS, MRCP, FRCP, FDS RCSeng, FGDP, PhD, Dip Ed teachers Med/Dent


Professor of Medicine in Relation to Oral Health

Telephone: +44 20 7882 7154
Room Number: G80, Blizard Building, Institute of Dentistry


Professor Fortune is Professor of Medicine in relation to Oral Health in the Centre for Clinical and Diagnostic Oral Sciences (CDOS). She graduated in both Dentistry and Medicine from University College, University of London. In 1992 she obtained her PhD in University of London. She is on the specialist register for Oral Medicine in Dentistry (GDC), and Immunology in Medicine (GMC). She was appointed Senior Lecturer in Immunology and Honorary Consultant in Oral Medicine at UMDS (Guys and St Thomas Hospital). In 1998 she was conferred the title of Professor of Oral Medicine at Leeds University.

In 2002 Professor Fortune was recruited to the position of Professor of Medicine in Relation to Oral Health at Queen Mary. She had previously held the positions of Head of Oral Medicine at Leeds University and Senior Lecturer in Immunology and Honorary Consultant in Oral Medicine at the United Medical and Dental Schools of Guy's and St Thomas' Hospitals.

She was appointed as The Dean and Head and Institute Director of Dentistry for Dentistry at Barts and The London in 2007-2013.She has extensive experience in teaching within both the undergraduate and postgraduate sector. Her expertise is in curriculum development, assessment methodology and quality assurance. She works in these areas both in the UK and abroad. She chaired Royal College of Surgeons examination committee for a number of years. She has being seminal in the reintroduction of the LDS RCSeng., which was the first licensed examination in Dentistry. She is one of the founding members of Inter-professional Education Network of Royal Society of Medicine 2013; Member of (UKHEAC) UK Healthcare Education Advisory Committee.

She works extensively with local communities and mentors’ doctors, dentists and scientists trying to navigate the complex environments of the HEIs and NHS.                                                                                                     

2016-Advisory Board member of Mosaic whose is mission to support disadvantaged children and young people from deprived communities in the UK.           

Professor Fortune played a leading role in the organisation, implementation and the delivery of three separate dental facilities for oral healthcare at the London Olympic and Paralympic Games. The organising medical team was awarded the prestigious Nursing Times award 2013. The Team of the Year Award celebrates new projects that demonstrate the value of teamwork in the UK health care sector.

Nationally and internationally her strategic focus has been on widening access and increasing uptake into higher education. In London she works with several schools to develop aspiration in schoolchildren from the earliest years. She chaired London Healthcare Education Widening Access Committee. The focus abroad has been to build capacity and increase uptake using non-traditional models of education and clinical training. An example is in-community and community outreach programs for teaching and training. The evidence shows that these approaches are   a productive, dynamic and efficient use of resource to deliver high quality teaching and training. She has played a major role internationally in health and education initiatives and remains committed to global collaboration to enhance health and education. Her current focus is to embed health and education within the contextual focus of national and societal cultures, and economics. Ongoing programs in Africa are with Global Knowledge Education Network (GKEN) an African diaspora group of academics and like-minded persons, with Universities in several countries to deliver and exploit technology for affordable access to health and education, through Sustainable Goals. In Speaker 2015- January stakeholder interest -EU Parliament. Later that year Co-chaired meeting in New York on UN sustainable Goals-focussing on countries in South America and Asia.

She was Clinical Director in 2008-2012 for Dentistry, Head and Neck including Maxillofacial surgery and ENT. Her clinical expertise is in Oral Medicine, Clinical Immunology and Oral manifestations of Systemic Disease and rare diseases is well recognized. Professor Fortune's standing within Oral Medicine is reflected by her election to the Council of the British Society of Oral Medicine in 2004 and to the role of President in 2007 and as President of Odontology section of Royal Society of Medicine in 2011. She was elected a Fellow of the Royal College of Physicians in 2007, FRCS of the Royal college of Surgeons in 2009 and awarded the Colyer Gold Medal in 2012 for teaching, research and clinical excellence.

Currently, - she is the Director of the Behçet’s Centre of Excellence in London.

In 2016 she led the bid for BD Centres UK and was awarded membership of the European Reference Network RITA (ERN).

Professor Fortune played a leading role in the organisation, implementation and the delivery of three separate dental facilities for oral healthcare at the London Olympic and Paralympic Games. The organising medical team was awarded the prestigious Nursing Times award 2013. The Team of the Year Award celebrates new projects that demonstrate the value of teamwork in the UK health care sector.

Professor Fortune's main research focus is epithelial biology, including mucosal disease and oral cancer, on which she has published extensively. She has a particular interest and expertise in Behçet's disease and is a member of the medical advisory panel to the Behçet's Syndrome Society. Together with Behçet's Society they secured funding to set up three dedicated Centres in England for the management of this condition. She is the Scientific Advisor to the International Society for Behçet's disease 2012-14. Current clinical trials are NIHR EME o2016-18 optimal utilization of biologic drugs in Behçet's Disease: a stratified medicine approach (co-applicant) and 2018- co-applicant with Professor Jonathan Grigg NIHR Global Health Research Group on improving asthma outcomes in African children at Queen Mary University of London.  (6 African countries)                                                                                                    

Further to this, she is a member of the Research Grants Committee (Hong Kong) - Biology and Medicine panel 2012-17. She also continues to work extensively with the EU research evaluation n an active manner. She was an evaluator for the FP programs and at present for Horizon 2020 MSCA as an evaluator and vice chair.

In 2004, she was awarded a CBE for services to dentistry. In 2012, she was awarded prestigious Colyer Gold Medal for significant contribution to the profession through their research, teaching and clinical work.


Centre: Centre for Oral Immunobiology and Regenerative Medicine


Research Interests:

Professor Fortune is the Centre Lead for CDOS which includes Oral Biology, Oral Microbiology, Oral Pathology, Oral Medicine, Oral Surgery and Oral and Maxillofacial Radiology. The Centre provides teaching support for all the above specialties in the undergraduate Dental curriculum and participates in BSc course. CDOS also runs postgraduate courses in Masters in Clinical Dental Science, Masters in Experimental Oral Sciences as well as a full programme of PhD students.

The centre has a very strong research focus. We have developed our research portfolio to encompass a basic and translational focus, which fits the wider research strategy of the Institute of Dentistry and QMUL. The Centre has invested in establishing a major research group in Oral Cancer within the Institute of Dentistry. We have built strong links with the local community, as well as international collaborators in countries where oral cancer has a major impact of health services. Oral cancer and immunity and infection research will form a major focus for us in the next 10 years.

The Oral Oncology research crosses several areas within the Institute of Dentistry and the Institutes of Cell and Molecular Biology, Cancer, as well as Engineering and Material Science at QMUL. Links within the Institute Of Dentistry are robust particularly with the Public Health group of Professor Croucher who has developed strong links with CRUK. A research driven clinical multidisciplinary clinic for the follow up of precancerous oral lesions will be embedded in the BLT academic units.

Development of Oral Cancer will not detract from the strong infection/inflammation research within CDOS. Indeed all specialties will have research embedded in both Oral Cancer and infection/inflammation. This research will be supported by the Clinical specialties within CDOS

Professor Fortune's primary research interests focus on the role of inflammation and immune related mucosal diseases. She is especially interested in the influence of the genetic profile on inflammatory mucosal disease; the microenvironment changes and the genetic basis of oro-facial systemic diseases; the influence of inflammatory status on wound healing and the prognosis and the regulation of healing in normal, fibrotic and ulcerative lesions affecting the oral mucosa.

In addition to this, she has been working in biometrics since 1996. The facial measurements for dysmorphology with Drs. LiFong Zu and Adegun have made a unique contribution to biometrics. This has now been used for accurate analysis for facial dysmorphology to assist clinical treatment. She has recently been working alongside Professor Dan Bader, Adegun, Tomlins and  Hagli-Pavli we develop a technique called Scattering Attenuation Microscopy (SAM) to be used for the early detection of oral cancer as well as other mucosal lesions. The pilot stage is complete. The in-clinical standardization of the technique is now taking with  Professor Bader, and Adegun together with an  international group to further develop the instrument.

Professor Fortune's clinical expertise lies in systemic manifestations of oral disease. Some of these are: specific mucosal immune mediated diseases
Professor Fortune is the Director of the London Centre of Excellence for Behçet's disease. She is leads the largest of the 3 national commissioned Centres in the UK. The multidisciplinary clinical team includes Professor Stanford, Professor Jawad, Dr. Kidd, Dr. Grigoriadou, and Dr. Buchanan. The research team includes Lesley Bergmeier, Hagli-Pavli, postdocs and PhD students. The clinic is protocol lead with outcomes which feed into the laboratory and clinical research. The centre also runs clinical trials as part of the UK Behçet’s Network. We work closely with the International Behçet’s Society, our European network of clinicians and researches and both our national and International patients’ organisation. Professor Fortune is on the executive of the International B Behçet’s Society

Professor Fortune's research interests are the immunology and outcomes of other mucosal diseases and systemic disease presenting in the Oral tissues, e.g. Renal diseases post renal transplant Haemato-oncology after bone marrow transplant and chemotherapy-Graft Versus Host disease.
In the aforementioned specialties, the mouth is an important site to assist in the diagnosis and monitor disease activity e.g. graft versus host disease, mucosal effects of changes in the oral microflora, or the direct effects of complicated medication regimes on the mucosa.
Gastroenterology (inflammatory bowel diseases)  - Professor Fortune has special expertise with patients with Orofacial granulomatous and Oral Crohn's disease. Her work in this area is part of the Biometrics program. Along with the clinical team she has provided input to several Paediatric Centres across the UK. Together with a major children's charity (CICRA) which funds their research, the team has prepared information leaflets for children and parents with this problem.
Immunology/auto inflammatory conditions - Professor Fortune is also involved in clinical research regarding the diagnosis of HIV/Aids and inflammatory conditions. It is not uncommon to make the diagnosis of HIV/Aids in her oral medicine clinic, with patients sent from the primary care sector.





Senusi A, Higgins S, Fortune F. The influence of oral health and psycho-social well-being on clinical outcomes in Behçet's disease. Rheumatol Int. 2018 Aug 27. doi: 10.1007/s00296-018-4117-y. [Epub ahead of print] PubMed PMID: 30151720.

Ozguler Y, Leccese P, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Çelik AF,Fortune F, Gaudric J, Gul A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D,Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G. Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. Rheumatology (Oxford). 2018 Aug 13. doi: 10.1093/rheumatology/key242. [Epub ahead of print] PubMed PMID: 30107448.

Leccese P, Ozguler Y, Christensen R, Esatoglu SN, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gül A, Kötter I, Mahr A, Moots RJ, Richter J, Saadoun D,Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H, Hatemi G. Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. Semin Arthritis Rheum.2018 May 19. pii: S0049-0172(18)30240-3. doi: 10.1016/j.semarthrit.2018.05.008.[Epub ahead of print] PubMed PMID: 29954598.

Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, Gaudric J, Gul A, Kötter I, Leccese P, Mahr A, Moots R, Ozguler Y, Richter J, Saadoun D, Salvarani C, Scuderi F, Sfikakis PP, Siva A, Stanford M, Tugal-Tutkun I, West R, Yurdakul S, Olivieri I, Yazici H. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018 Jun;77(6):808-818. doi:10.1136/annrheumdis-2018-213225. Epub 2018 Apr 6. PubMed PMID: 29625968.

Senusi AA, Ola D, Mather J, Mather J, Fortune F. Behçet's syndrome and health-related quality of life: influence of symptoms, lifestyle and employment status. Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):43-50. Epub 2017 Jun 8.  PubMed PMID: 28598773. 

Moots RJ, Fortune F, Situnayake D. The Behçet's centres of excellence. Rheumatology (Oxford). 2018 Apr 1;57(4):594-595. doi:10.1093/rheumatology/kex037. PubMed PMID: 28340170.

Hasan MS, Ryan PL, Bergmeier LA, Fortune F. Circulating NK cells and their subsets in Behçet's disease. Clin Exp Immunol. 2017 May;188(2):311-322. doi:10.1111/cei.12939. Epub 2017 Mar 13. PubMed PMID: 28170096; PubMed Central PMCID: mZumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M;

Host-Directed Therapies Network consortium. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.Lancet Infect Dis. 2016 Apr;16(4):e47-63. doi: 10.1016/S1473-3099(16)00078-5.Review. PubMed PMID: 27036359.

Liu J, Rawlinson SCF, Hill RG, Fortune F. Fluoride incorporation in highphosphate containing bioactive glasses and in vitro osteogenic, angiogenic and antibacterial effects. Dent Mater. 2016 Oct;32(10):e221-e237. doi:10.1016/ Epub 2016 Jul 25. PubMed PMID: 27461261.

Liu J, Rawlinson SC, Hill RG, Fortune F. Strontium-substituted bioactive glasses in vitro osteogenic and antibacterial effects. Dent Mater. 2016 Mar;32(3):412-22. doi: 10.1016/ Epub 2016 Jan 8. PubMed PMID: 26777094.

Hasan MS, Bergmeier LA, Petrushkin H, Fortune F. Gamma Delta (γδ) T Cells and Their Involvement in Behçet's Disease. J Immunol Res. 2015;2015:705831. doi:10.1155/2015/705831. Epub 2015 Oct 11. Review. PubMed PMID: 26539557; PubMed Central PMCID: PMC4619955.

Petrushkin HJ, Stanford M, Fortune F, Jawad A. Improving morbidity and mortality in peripheral ulcerative keratitis associated with rheumatoid arthritis. Clin Exp Rheumatol. 2016 Jan-Feb;34(1 Suppl 95):S18-9. Epub 2015 Oct 30. PubMed PMID: 26517314.

Senusi A, Seoudi N, Bergmeier LA, Fortune F. Genital ulcer severity score and genital health quality of life in Behçet's disease. Orphanet J Rare Dis. 2015 Sep 22;10(1):117. doi: 10.1186/s13023-015-0341-7. PubMed PMID: 26394620; PubMed Central PMCID: PMC4579635.

Seoudi N, Bergmeier LA, Hagi-Pavli E, Bibby D, Fortune F. The seroprevalence and salivary shedding of herpesviruses in Behçet's syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015 Jun 5;7:27156. doi:10.3402/jom.v7.27156. eCollection 2015. PubMed PMID: 26051327; PubMed Central PMCID: PMC4458513

Seoudi N, Bergmeier LA, Drobniewski F, Paster B, Fortune F. The oral mucosal and salivary microbial community of Behçet's syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015 Jun 1;7:27150. doi: 10.3402/jom.v7.27150. eCollection 2015. PubMed PMID: 26037240; PubMed Central PMCID: PMC4452653.

Petrushkin H, Hasan MS, Stanford MR, Fortune F, Wallace GR. Behçet's Disease: Do Natural Killer Cells Play a Significant Role? Front Immunol. 2015 Mar 24;6:134. doi: 10.3389/fimmu.2015.00134. eCollection 2015. Review. PubMed PMID: 25852697; PubMed Central PMCID: PMC4371743.

Petrushkin H, Stanford M, Fortune F, Jawad AS. Clinical Review: Familial Mediterranean Fever-An Overview of Pathogenesis, Symptoms, Ocular Manifestations, and Treatment. Ocul Immunol Inflamm. 2015 Aug 24:1-9. [Epub ahead of print] PubMed PMID: 25760918.

Gadhia T, Adegun OK, Fortune F. Brown tumours: widespread involvement of multiple maxillofacial bones and cervical spine. BMJ Case Rep. 2014 Nov 14;2014. pii: bcr2014207140. doi: 10.1136/bcr-2014-207140. PubMed PMID: 25398922.

Hamedi M, Bergmeier LA, Hagi-Pavli E, Vartoukian SR, Fortune F. Differential expression of suppressor of cytokine signalling proteins in Behçet's disease. Scand J Immunol. 2014 Nov;80(5):369-76. doi: 10.1111/sji.12211. PubMed PMID: 25207681.

Adegun OK, Abdelghani A, Fortune F. Oral manifestation of plantar-palmar fibromatosis. BMJ Case Rep. 2014 Aug 14;2014. pii: bcr2014204962. doi: 10.1136/bcr-2014-204962. PubMed PMID: 25123572.

Wright D, Muirhead V, Weston-Price S, Fortune F. Type 2 diabetes risk screening in dental practice settings: a pilot study. Br Dent J. 2014 Apr;216(7):E15. doi: 10.1038/sj.bdj.2014.250. PubMed PMID: 24722119.

Adegun OK, Zou L, Willis A, Fortune F. Facial biometrics: a novel technique for evaluation of morphological changes in orofacial Crohn's disease. BMJ Case Rep. 2013 Nov 20;2013. pii: bcr2013010460. doi: 10.1136/bcr-2013-010460. PubMed PMID: 24259527; PubMed Central PMCID: PMC3841427.

Needleman I, Ashley P, Petrie A, Fortune F, Turner W, Jones J, Niggli J, Engebretsen L, Budgett R, Donos N, Clough T, Porter S. Oral health and impact on performance of athletes participating in the London 2012 Olympic Games: a cross-sectional study. Br J Sports Med. 2013 Nov;47(16):1054-8. doi: 10.1136/bjsports-2013-092891. Epub 2013 Sep 24. PubMed PMID: 24068332; PubMed Central PMCID: PMC3812828.

Seoudi N, Bergmeier LA, Hagi-Pavli E, Bibby D, Curtis MA, Fortune F. The role of TLR2 and 4 in Behcet's disease pathogenesis. Innate Immun. 2013 Aug 12. [Epub ahead of print] PubMed PMID: 23940075.

Zou L, Adegun OK, Willis A, Fortune F. Facial biometrics of peri-oral changes in Crohn's disease. Lasers Med Sci. 2013 Feb 24. [Epub ahead of print] PMID:

Adegun OK, Tomlins PH, Hagi-Pavli E, Bader DL, Fortune F. Quantitative optical coherence tomography of fluid-filled oral mucosal lesions. Lasers Med Sci. 2012 Sep 21. [Epub ahead of print] PubMed PMID: 22996049.

Tsang SM, Brown L, Gadmor H, Gammon L, Fortune F, Wheeler A, Wan H. Desmoglein 3 acting as an upstream regulator of Rho GTPases, Rac-1/Cdc42 in the regulation of actin organisation and dynamics. Exp Cell Res. 2012 Nov 1;318(18):2269-83. doi: 10.1016/j.yexcr.2012.07.002. Epub 2012 Jul 13. PubMed PMID: 22796473.

Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G, Mahendra P, Taylor PC, Shah P, Lightman S, Fortune F, Kibbler C, Andreyev J, Albanese A, Hadzic N, Potter MN, Shaw BE; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol. 2012 Jul;158(1):62-78. doi: 10.1111/j.1365-2141.2012.09131.x. Epub 2012 Apr 26. PubMed PMID: 22533889.

Pitiyage GN, Lim KP, Gemenitzidis E, Teh MT, Waseem A, Prime SS, Tilakaratne WM, Fortune F, Parkinson EK. Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 (TIMPs -1 and -2) in fibroblasts are early indicators of oral sub-mucous fibrosis and ageing. J Oral Pathol Med. 2012 Jul;41(6):454-62. doi: 10.1111/j.1600-0714.2012.01129.x. Epub 2012 Mar 3. PubMed PMID: 22385081.

Tsang SM, Brown L, Lin K, Liu L, Piper K, O'Toole EA, Grose R, Hart IR, Garrod DR, Fortune F, Wan H. Non-junctional human desmoglein 3 acts as an upstream regulator of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis of pemphigus vulgaris. J Pathol. 2012 May;227(1):81-93. doi: 10.1002/path.3982. Epub 2012 Feb 17. PubMed PMID: 22294297.

Aggarwal VR, Palmer NO, Nelson P, Ladwa R, Fortune F. Proposed career pathway for clinical academic general dental practitioners. Prim Dent Care. 2011 Oct;18(4):155-60. PubMed PMID: 21968042.

Adegun OK, Tomlins PH, Hagi-Pavli E, McKenzie G, Piper K, Bader DL, Fortune F. Quantitative analysis of optical coherence tomography and histopathology images of normal and dysplastic oral mucosal tissues. Lasers Med Sci. 2012 Jul;27(4):795-804. Epub 2011 Aug 18. PubMed PMID: 21850480.

Macey M, Hagi-Pavli E, Stewart J, Wallace GR, Stanford M, Shirlaw P, Fortune F. Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behçet's disease. Rheumatology (Oxford). 2011 Oct;50(10):1849-59. Epub 2011 Jun 29. PubMed PMID: 21719422.

Durrani O, Banahan K, Sheedy FJ, McBride L, Ben-Chetrit E, Greiner K, Vaughan RW, Kondeatis E, Hamburger J, Fortune F, Stanford MR, Murray PI, O'Neill LA, Wallace GR. TIRAP Ser180Leu polymorphism is associated with Behcet's disease. Rheumatology (Oxford). 2011 Oct;50(10):1760-5. Epub 2011 Jun 24. PubMed PMID: 21705416.

Mannan T, Jing S, Foroushania SH, Fortune F, Wan H. RNAi-mediated inhibition of the desmosomal cadherin (desmoglein 3) impairs epithelial cell proliferation. Cell Prolif. 2011 Aug;44(4):301-10. doi: 10.1111/j.1365-2184.2011.00765.x. PubMed PMID: 21702856.

Kerr AR, Warnakulasuriya S, Mighell AJ, Dietrich T, Nasser M, Rimal J, Jalil A, Bornstein MM, Nagao T, Fortune F, Hazarey VH, Reichart PA, Silverman S, Johnson NW. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral Dis. 2011 Apr;17 Suppl 1:42-57. doi: 10.1111/j.1601-0825.2011.01791.x. Review. PubMed PMID: 21382138.

Pitiyage GN, Slijepcevic P, Gabrani A, Chianea YG, Lim KP, Prime SS, Tilakaratne WM, Fortune F, Parkinson EK. Senescent mesenchymal cells accumulate in human fibrosis by a telomere-independent mechanism and ameliorate fibrosis through matrix metalloproteinases. J Pathol. 2011 Apr;223(5):604-17. doi: 10.1002/path.2839. Epub 2011 Feb 21. PubMed PMID: 21341274.

Tomlins PH, Adegun O, Hagi-Pavli E, Piper K, Bader D, Fortune F. Scattering attenuation microscopy of oral epithelial dysplasia. J Biomed Opt. 2010 Nov-Dec;15(6):066003. PubMed PMID: 21198177.

Moutasim KA, Jenei V, Sapienza K, Marsh D, Weinreb PH, Violette SM, Lewis MP, Marshall JF, Fortune F, Tilakaratne WM, Hart IR, Thomas GJ. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J Pathol. 2011 Feb;223(3):366-77. doi: 10.1002/path.2786. Epub 2010 Oct 25. PubMed PMID: 21171082.

Tsang SM, Liu L, Teh MT, Wheeler A, Grose R, Hart IR, Garrod DR, Fortune F, Wan H. Desmoglein 3, via an interaction with E-cadherin, is associated with activation of Src. PLoS One. 2010 Dec 3;5(12):e14211. PubMed PMID: 21151980; PubMed Central PMCID: PMC2997060.

Teh MT, Parkinson EK, Thurlow JK, Liu F, Fortune F, Wan H. A molecular study of desmosomes identifies a desmoglein isoform switch in head and neck squamous cell carcinoma. J Oral Pathol Med. 2011 Jan;40(1):67-76. doi: 10.1111/j.1600-0714.2010.00951.x. Epub 2010 Oct 4. PubMed PMID: 20923451.

Bernabé E, Marcenes W, Mather J, Phillips C, Fortune F. Impact of Behçet's syndrome on health-related quality of life: influence of the type and number of symptoms. Rheumatology (Oxford). 2010 Nov;49(11):2165-71. Epub 2010 Jul 30. PubMed PMID: 20675710.

Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I,Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WE, Cho YH, Bang D, O'Shea J, Wallace GR, Gadina M, Kastner DL, Gül A. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet. 2010 Aug;42(8):698-702. Epub 2010 Jul 11. PubMed PMID: 20622878; PubMed Central PMCID: PMC2923807.

Waseem A, Ali M, Odell EW, Fortune F, Teh MT. Downstream targets of FOXM1: CEP55 and HELLS are cancer progression markers of head and neck squamous cell carcinoma. Oral Oncol. 2010 Jul;46(7):536-42. Epub 2010 Apr 18. PubMed PMID: 20400365.

Nunn H, Lalli A, Fortune F, Croucher R. Oral cancer screening in the Bangladeshi community of Tower Hamlets: a social model. Br J Cancer. 2009 Dec 3;101 Suppl 2:S68-72. PubMed PMID: 19956167; PubMed Central PMCID: PMC2790708.

Kappen JH, Wallace GR, Stolk L, Rivadeneira F, Uitterlinden AG, van Daele PL, Laman JD, Kuijpers RW, Baarsma GS, Stanford MR, Fortune F, Madanat W, van Hagen PM, van Laar JA. Low prevalence of NOD2 SNPs in Behçet's disease suggests protective association in Caucasians. Rheumatology (Oxford). 2009 Nov;48(11):1375-7. Epub 2009 Sep 11. PubMed PMID: 19748964.

Mumcu G, Niazi S, Stewart J, Hagi-Pavli E, Gokani B, Seoudi N, Ergun T, Yavuz S, Stanford M, Fortune F, Direskeneli H. Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease. J Oral Pathol Med. 2009 May;38(5):406-9. Epub 2009 Mar 2. PubMed PMID: 19298505.

Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, Sugden D, Thurlow JK, Cheong SC, Teo SH, Wan H, Waseem A, Parkinson EK, Fortune F, Teh MT. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One. 2009;4(3):e4849. Epub 2009 Mar 16. PubMed PMID: 19287496; PubMed Central PMCID: PMC2654098.

Curnow SJ, Pryce K, Modi N, Knight B, Graham EM, Stewart JE, Fortune F, Stanford MR, Murray PI, Wallace GR. Serum cytokine profiles in Behçet's disease: is there a role for IL-15 in pathogenesis? Immunol Lett. 2008 Nov 16;121(1):7-12. Epub 2008 Aug 13. PubMed PMID: 18706446.

Bye L, Modi N, Stanford MR, Kondeatis E, Vaughan R, Fortune F, Kanawati C, Ben-Chetrit E, Ghabra M, Murray PI, Wallace GR. CTLA-4 polymorphisms are not associated with ocular inflammatory disease. Tissue Antigens. 2008 Jul;72(1):49-53. Epub 2008 May 20. PubMed PMID: 18498289.

Tilakaratne WM, Freysdottir J, Fortune F. Orofacial granulomatosis: review on aetiology and pathogenesis. J Oral Pathol Med. 2008 Apr;37(4):191-5. Review. PubMed PMID: 18321344.

Teh MT, Tilakaratne WM, Chaplin T, Young BD, Ariyawardana A, Pitiyage G, Lalli A, Stewart JE, Hagi-Pavli E, Cruchley A, Waseem A, Fortune F. Fingerprinting genomic instability in oral submucous fibrosis. J Oral Pathol Med. 2008 Aug;37(7):430-6. Epub 2008 Feb 17. PubMed PMID: 18284545.

Tilakaratne WM, Iqbal Z, Teh MT, Ariyawardana A, Pitiyage G, Cruchley A, Stewart JE, Hagi-Pavli E, Lalli A, Waseem A, Parkinson EK, Fortune F. Upregulation of HIF-1alpha in malignant transformation of oral submucous fibrosis. J Oral Pathol Med. 2008 Jul;37(6):372-7. Epub 2008 Jan 19. PubMed PMID: 18221327.

Lalli A, Tilakaratne WM, Ariyawardana A, Fitchett C, Leigh IM, Hagi-Pavli E, Cruchley AT, Parkinson EK, Teh MT, Fortune F, Waseem A. An altered keratinocyte phenotype in oral submucous fibrosis: correlation of keratin K17 expression with disease severity. J Oral Pathol Med. 2008 Apr;37(4):211-20. Epub 2008 Jan 17. PubMed PMID: 18205743.

Kose O, Stewart J, Waseem A, Lalli A, Fortune F. Expression of cytokeratins, adhesion and activation molecules in oral ulcers of Behçet's disease. Clin Exp Dermatol. 2008 Jan;33(1):62-9. Epub 2007 Nov 3. PubMed PMID: 17983454.

Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med. 2007 Nov;36(10):594-603. PubMed PMID: 17944752.

Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham E, Fortune F, Madanat W, Kanawati C, Ghabra M, Murray PI, Wallace GR. The association of the PTPN22 620W polymorphism with Behcet's disease. Ann Rheum Dis. 2007 Nov;66(11):1531-3. Epub 2007 Jul 27. PubMed PMID: 17660222; PubMed Central PMCID: PMC2111602.

Summers SA, Tilakaratne WM, Fortune F, Ashman N. Renal disease and the mouth. Am J Med. 2007 Jul;120(7):568-73. Review. PubMed PMID: 17602925.

Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol. 2006 Nov-Dec;35(6):472-5. PubMed PMID: 17343257.

Wallace GR, Kondeatis E, Vaughan RW, Verity DH, Chen Y, Fortune F, Madanat W, Kanawati CA, Graham EM, Stanford MR. IL-10 genotype analysis in patients with Behçet's disease. Hum Immunol. 2007 Feb;68(2):122-7. Epub 2006 Dec 27. PubMed PMID: 17321902.

Freysdottir J, Zhang S, Tilakaratne WM, Fortune F. Oral biopsies from patients with orofacial granulomatosis with histology resembling Crohn's disease have a prominent Th1 environment. Inflamm Bowel Dis. 2007 Apr;13(4):439-45. PubMed PMID: 17206709.

Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis. 2006 May;12(3):271-7. PubMed PMID: 16700735.

Ahmad T, Zhang L, Gogus F, Verity D, Wallace G, Madanat W, Fayyad F, James T, Neville M, Kanawati C, Fortune F, Celik A, Stanford M, Jewell DP, Marshall SE. CARD15 polymorphisms in Behçet's disease. Scand J Rheumatol. 2005 May-Jun;34(3):233-7. PubMed PMID: 16134731.

Yang X, Ahmad T, Gogus F, Verity D, Wallace GR, Madanat W, Kanawati CA, Stanford MR, Fortune F, Jewell DP, Marshall SE. Analysis of the CC chemokine receptor 5 (CCR5) Delta32 polymorphism in Behçet's disease. Eur J Immunogenet. 2004 Feb;31(1):11-4. Erratum in: Eur J Immunogenet. 2005 Jun;32(3):219. Verity, D [added]. PubMed PMID: 15009175.

Stark P, Fortune F. Teaching clinical skills in developing countries: are clinical skills centres the answer? Educ Health (Abingdon). 2003 Nov;16(3):298-306. PubMed PMID: 14741878.

Chen Y, Vaughan RW, Kondeatis E, Fortune F, Graham EM, Stanford MR, Wallace GR. Chemokine gene polymorphisms associate with gender in patients with uveitis. Tissue Antigens. 2004 Jan;63(1):41-5. PubMed PMID: 14651522.

Chen Y, Stanford MR, Wallace GR, Vaughan RW, Kondeatis E, Fortune F. Factor V Leiden mutation does not correlate with retinal vascular occlusion in white patients with Behçet's disease. Br J Ophthalmol. 2003 Aug;87(8):1048-9. PubMed PMID: 12881356; PubMed Central PMCID: PMC1771783.

Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003 Mar;48(3):807-13. PubMed PMID: 12632436.

Fortune F. Can you catch Behçet's disease? J Lab Clin Med. 2003 Jan;141(1):5-6. PubMed PMID: 12518164.

Farmer I, Freysdottir J, Dalghous AM, Fortune F. Expression of adhesion and activation molecules in human buccal epithelial cell lines and normal human buccal epithelium in situ. J Oral Pathol Med. 2001 Feb;30(2):113-20. PubMed PMID: 11168856.